Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 24;20(3):367–379. doi: 10.1093/neuonc/nox160

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

PMC Copyright notice

Fig. 1 — Copy number variations in primary glioblastoma according to MGMT promoter methylation. (A) Left panel: overall survival of 143 glioblastoma patients with IDH1 wildtype tumors according to MGMT promoter methylation. Right panel: survival analysis of patients with tumors from the dataset from TCGA regardless of the treatment. (B) Left panel: survival analysis of tumors of the TCGA glioblastoma database not receiving chemotherapy according to MGMT promoter methylation. Right panel: survival analysis of the dataset from TCGA treated with chemotherapy. (C) Graphical illustration of the percentage of CNV in the mMGMT and uMGMT groups. (D) Relative fractions of DNA copy number variations detected in the database from TCGA according to MGMT promoter methylation. Shown are the means ± standard deviation. (E) Average fraction of mutations detected in the dataset from TCGA according to MGMT promoter methylation. Shown are the means ± standard deviation.